Hims & Hers launches GLP-1 tracker in response to FDA's shortage decision
Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...
Becker's Hospital Review10h
Hims & Hers launches GLP-1 tracker amid shortages
Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.
Hims & Hers launching GLP-1 tracker, Yahoo Finance reports
In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...
After Another Blowout Quarter of Surging Revenue, Is Hims & Hers Stock a Once-in-a-Decade Buy?
Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...
Seeking Alpha9d
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...
Modern Healthcare2d
Hims & Hers, Talkspace among Q3 winners in digital health
Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.
Drug Store News1d
Hims & Hers Health plans to launch generic of Novo Nordisk's Victoza
Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...
Yahoo Finance3d
Hims & Hers' Shares Jump 17%: Explosive Growth, Insider Confidence, and Big Money Moves
Analysts are buzzing as well, with TD Cowen raising its price target to $28, citing HIMS' diverse revenue streams and ...